AR067506A1 - Derivados de quinazolinamida - Google Patents
Derivados de quinazolinamidaInfo
- Publication number
- AR067506A1 AR067506A1 ARP080102977A ARP080102977A AR067506A1 AR 067506 A1 AR067506 A1 AR 067506A1 AR P080102977 A ARP080102977 A AR P080102977A AR P080102977 A ARP080102977 A AR P080102977A AR 067506 A1 AR067506 A1 AR 067506A1
- Authority
- AR
- Argentina
- Prior art keywords
- noa
- noh
- nnha
- nnh2
- mono
- Prior art date
Links
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 6
- 125000004429 atom Chemical group 0.000 abstract 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 2
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 abstract 2
- 101100293593 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nar-1 gene Proteins 0.000 abstract 2
- 241001103145 Pentas Species 0.000 abstract 2
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000565 sulfonamide group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- ABVYZAMNSCVWJA-UHFFFAOYSA-N quinazoline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=NC=C21 ABVYZAMNSCVWJA-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
Abstract
Los nuevos derivados de quinazolinamida de la formula (1) en donde R1 es H, A, (CH2)nCONH2, (CH2)nCONHA, (CH2)nCONAA', Hal, (CH2)nNH2, (CH2)nNHA, (CH2)nNAA', CN, NO2, (CH2)nAr, OAr, (CH2)nCOOH, (CH2)nCOOA, (CH2)nOH, (CH2)nOA, (CH2)nHet, COHet, C:::C-CH2SiA2A', C:::CH, C:::C-A, CH=CH-Ar1, CH=CH-COOA, CH2CH(OH)CH2OH, O(CH2)nOH, NH(CH2)nOH, O(CH2)nOA, NH(CH2)nOA, O(CH2)nNHA, NH(CH2)nNHA, NR4R5, (CH2)nCOOA, (CH2)nCONH(CH2)2CN, NH(CH2)nAr o CH=CH-COOH, R2 es H, A, (CH2)nAr, (CH2)nHet, (CH2)nOH, (CH2)nOA, (CH2)nNHHet, (CH2)nSA o (CH2)nCH(OH)Ar, R3 es A, (CH2)nAr, (CH2)nHet, (CH2)nCN, (CH2)nNH2, (CH2)nNHA, (CH2)nNAA', (CH2)nOH, (CH2)nOA o (CH2)nNHHet, R2 y R3 también son, junto con el átomo de N al que están unidos, un heterociclo mono- o bicíclico saturado, insaturado o aromático no sustituido o mono-, di- o trisustituido con Hal, A, (CH2)nOH, (CH2)nOA y/u =O (oxígeno del carbonilo), que puede contener otros 1 a 3 átomos de N, O y/o S, R4, R5 son, de modo independiente entre sí, (CH2)nOH, (CH2)nOA, (CH2)nNH2, (CH2)nNHA o (CH2)nNAA', Ar es fenilo, naftilo, tetrahidronaftilo o bifenilo no sustituido o mono-, di-, tri-, tetra- o pentasustituido con A, Hal, (CH2)nOA, (CH2)nOH, (CH2)nCN, SA, SOA, SO2A, NO2, C:::CH, (CH2)nCOOH, CHO, (CH2)nCOOA, CONH2, CONHA, CONAA', NHCOA, CH(OH)A, (CH2)nNH2, (CH2)nNHA, (CH2)nNAA', (CH2)nNAAr1, O(CH2)nHet1, (CH2)nHet1, COO(CH2)nAr1, (CH2)nNHSO2A, (CH2)nOAr1, O(CH2)nAr1, SO2NH(CH2)nNH2, SO2NH2, SO2NHA, SO2NAA', CONHAr1, CONH(CH2)nCOOA, CONH(CH2)nCOOH, NHCO(CH2)nCOOA, NHCO(CH2)nCOOH, CONH(CH2)nNH2, CONH(CH2)nNHA, CONH(CH2)nNAA', CONH(CH2)nCN, NHCOHet, SO2Het, COHet y/o (CH2)nCH(NH2)COOH, Ar1 es fenilo no sustituido o mono-, di-, tri-, tetra- o pentasustituido con A, Hal y/u OA, Het es un heterociclo mono- o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que no está sustituido o que puede estar mono-, di- o trisustituido con A, (CH2)nOA, (CH2)nOH, Ar1, SH, S(O)mA, Hal, NO2, CN, COA, CHO, COOA, COObencilo, CONH2, CONHA, CONAA', SO2NH2, (CH2)nNH2, (CH2)nNHA, (CH2)nNAA', NHSO2A y/u =O (oxígeno del carbonilo), Het1 es un heterociclo mono- o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que no está sustituido o que está mono- o disustituido con A, OA, OH, Hal, CN y/u =O (oxígeno del carbonilo), A, A' son, de modo independiente entre sí, alquilo no ramificado o ramificado C1-10, en donde 1-3 grupos CH2 no adyacentes pueden estar reemplazados por O, S, SO, SO2, NH, NNe o Net y/o también 1-5 átomos de H también pueden estar reemplazados por F, OH y/o Cl, Alk1 es alquilo cíclico C3-8 o cicloalquilalquileno, en donde 1-5 átomos de H pueden estar reemplazados por F, OH y/o Cl, Alk1 es alquenilo o alquinilo C2-6, m es 0, 1 o 2, n es 0, 1, 2, 3 o 4, así como sus derivados, sales, solvatos y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones. Son inhibidores de la HSP90 y pueden ser utilizados para preparar un medicamento para el tratamiento de enfermedades en las que la inhibicion, la regulacion y/o la modulacion de la HSP90 desempena un papel importante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007032739A DE102007032739A1 (de) | 2007-07-13 | 2007-07-13 | Chinazolinamidderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067506A1 true AR067506A1 (es) | 2009-10-14 |
Family
ID=40121496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102977A AR067506A1 (es) | 2007-07-13 | 2008-07-11 | Derivados de quinazolinamida |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8501754B2 (es) |
| EP (1) | EP2164833B1 (es) |
| JP (1) | JP5457343B2 (es) |
| KR (1) | KR20100044846A (es) |
| CN (1) | CN101743229B (es) |
| AR (1) | AR067506A1 (es) |
| AU (1) | AU2008278032B2 (es) |
| BR (1) | BRPI0814236A2 (es) |
| CA (1) | CA2694475C (es) |
| DE (1) | DE102007032739A1 (es) |
| EA (1) | EA017585B1 (es) |
| ES (1) | ES2538218T3 (es) |
| IL (1) | IL203206A (es) |
| WO (1) | WO2009010139A2 (es) |
| ZA (1) | ZA201001058B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008061214A1 (de) * | 2008-12-09 | 2010-06-10 | Merck Patent Gmbh | Chinazolinamidderivate |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| US20120316171A1 (en) * | 2009-11-05 | 2012-12-13 | Tamas Oravecz | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer |
| DE102009054302A1 (de) | 2009-11-23 | 2011-05-26 | Merck Patent Gmbh | Chinazolinderivate |
| DE102010046837A1 (de) * | 2010-09-29 | 2012-03-29 | Merck Patent Gmbh | Phenylchinazolinderivate |
| WO2012069146A1 (en) * | 2010-11-24 | 2012-05-31 | Merck Patent Gmbh | Quinazoline carboxamide azetidines |
| GB2486631A (en) * | 2010-12-01 | 2012-06-27 | Univ Sheffield | Phenol/quinone boronic acids/esters and method of preparation thereof |
| TW201311149A (zh) * | 2011-06-24 | 2013-03-16 | Ishihara Sangyo Kaisha | 有害生物防治劑 |
| AU2014227992A1 (en) * | 2013-03-15 | 2015-11-05 | Rexahn Pharmaceuticals, Inc. | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl) methanone compounds as cancer cell growth inhibitors |
| US10138212B2 (en) | 2015-02-06 | 2018-11-27 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as A2A antagonist |
| EP3317278B1 (en) * | 2015-07-01 | 2021-04-14 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| CN108473435A (zh) | 2015-10-05 | 2018-08-31 | 纽约市哥伦比亚大学理事会 | 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗 |
| JP6836591B2 (ja) * | 2016-07-19 | 2021-03-03 | 日本化薬株式会社 | 撮像素子用光電変換素子用材料及びそれを含む光電変換素子 |
| CA3068128A1 (en) * | 2017-06-26 | 2019-01-03 | North & South Brother Pharmacy Investment Company Limited | Dihydropyrimidine compounds and uses thereof in medicine |
| CN107382976A (zh) * | 2017-07-04 | 2017-11-24 | 孙秀芹 | 一种治疗盆腔炎的化合物及制备方法和应用 |
| CN107488168A (zh) * | 2017-07-18 | 2017-12-19 | 黄绍菊 | 一种治疗盆腔炎的化合物及制备方法和应用 |
| EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
| TWI853814B (zh) | 2018-05-31 | 2024-09-01 | 南韓商Ｃ＆Ｃ新藥研究所 | 雜環衍生物及其用途 |
| US20230250088A1 (en) * | 2020-07-15 | 2023-08-10 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US12503436B2 (en) | 2021-08-10 | 2025-12-23 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with STING activity |
| TW202400600A (zh) * | 2022-06-16 | 2024-01-01 | 美商昂勝醫療科技股份有限公司 | 喹唑啉衍生物、其組成物及方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| WO1999051223A1 (en) | 1998-04-03 | 1999-10-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
| EP1161231A2 (en) | 1999-03-12 | 2001-12-12 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Method of inhibiting a chaperone protein |
| JP2003528886A (ja) | 2000-03-24 | 2003-09-30 | デューク・ユニバーシティ | Ｃｒｐ９４−リガンド相互作用の特徴付けおよびそれに関連する精製、スクリーニングおよび治療法 |
| WO2002002123A1 (en) | 2000-06-29 | 2002-01-10 | Trustees Of Boston University | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders |
| EP1322325A4 (en) | 2000-07-20 | 2004-09-15 | Merck & Co Inc | INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS |
| AU2001292548B2 (en) | 2000-07-28 | 2005-06-16 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
| US6982274B2 (en) | 2001-04-16 | 2006-01-03 | Eisai Co., Ltd. | 1H-indazole compound |
| AU2002356922A1 (en) | 2001-11-09 | 2003-05-26 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
| WO2006010595A1 (en) | 2004-07-27 | 2006-02-02 | Novartis Ag | Inhibitors of hsp90 |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| DE102005022977A1 (de) * | 2005-05-19 | 2006-12-07 | Merck Patent Gmbh | Phenylchinazolinderivate |
-
2007
- 2007-07-13 DE DE102007032739A patent/DE102007032739A1/de not_active Withdrawn
-
2008
- 2008-06-16 WO PCT/EP2008/004846 patent/WO2009010139A2/de not_active Ceased
- 2008-06-16 CA CA2694475A patent/CA2694475C/en not_active Expired - Fee Related
- 2008-06-16 US US12/668,864 patent/US8501754B2/en not_active Expired - Fee Related
- 2008-06-16 KR KR1020107003221A patent/KR20100044846A/ko not_active Withdrawn
- 2008-06-16 ES ES08773474T patent/ES2538218T3/es active Active
- 2008-06-16 AU AU2008278032A patent/AU2008278032B2/en not_active Ceased
- 2008-06-16 EA EA201000098A patent/EA017585B1/ru not_active IP Right Cessation
- 2008-06-16 JP JP2010515363A patent/JP5457343B2/ja not_active Expired - Fee Related
- 2008-06-16 CN CN2008800245618A patent/CN101743229B/zh not_active Expired - Fee Related
- 2008-06-16 EP EP08773474.5A patent/EP2164833B1/de not_active Not-in-force
- 2008-06-16 BR BRPI0814236-0A2A patent/BRPI0814236A2/pt not_active IP Right Cessation
- 2008-07-11 AR ARP080102977A patent/AR067506A1/es unknown
-
2010
- 2010-01-07 IL IL203206A patent/IL203206A/en not_active IP Right Cessation
- 2010-02-12 ZA ZA2010/01058A patent/ZA201001058B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5457343B2 (ja) | 2014-04-02 |
| CA2694475A1 (en) | 2009-01-22 |
| US20100234324A1 (en) | 2010-09-16 |
| AU2008278032B2 (en) | 2013-03-28 |
| AU2008278032A1 (en) | 2009-01-22 |
| ES2538218T3 (es) | 2015-06-18 |
| EP2164833B1 (de) | 2015-04-15 |
| CN101743229B (zh) | 2013-08-14 |
| US8501754B2 (en) | 2013-08-06 |
| ZA201001058B (en) | 2010-11-24 |
| EP2164833A2 (de) | 2010-03-24 |
| KR20100044846A (ko) | 2010-04-30 |
| WO2009010139A2 (de) | 2009-01-22 |
| CN101743229A (zh) | 2010-06-16 |
| DE102007032739A1 (de) | 2009-01-15 |
| WO2009010139A3 (de) | 2009-03-12 |
| BRPI0814236A2 (pt) | 2015-01-06 |
| EA017585B1 (ru) | 2013-01-30 |
| IL203206A (en) | 2015-03-31 |
| EA201000098A1 (ru) | 2010-06-30 |
| CA2694475C (en) | 2015-07-28 |
| JP2010533132A (ja) | 2010-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR082722A1 (es) | Derivados de pirimidina | |
| AR067082A1 (es) | Derivados de indazolamida, proceso de preparacion, medicamentos que los contienen y usos de los mismos, fundamentalmente, como agentes antitumorales y/o antivirales. | |
| AR074493A1 (es) | Derivados de quinazolinamida | |
| AR061735A1 (es) | Derivados de indazol, composiciones farmaceuticas y uso de los mismos | |
| AR082726A1 (es) | Derivados de triazolopirazina | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| AR070649A1 (es) | Derivados de 1,3- dihidro -isoindol | |
| AR073055A1 (es) | Derivados biciclicos de triazol | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| AR077488A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de autotaxina, medicamentos que los contienen y uso de los mismos para el tratamiento y/o prevencion de cancer y enfermedades tumorales. | |
| AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
| AR096235A1 (es) | Arilquinazolinas | |
| AR068749A1 (es) | Derivados de n-(pirazol-3-il)-benzamida | |
| AR078313A1 (es) | Derivados de piridinil-imidazolona inhibidores de quinasas pi3k,composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias, entre otras | |
| AR054047A1 (es) | Derivados de fenilquinazolina | |
| AR052482A1 (es) | Derivados de triazol como inhibidores de hsp90 | |
| AR072098A1 (es) | Derivados de pirrolidina como inhibidores de metap-2 | |
| AR081828A1 (es) | Compuestos de biguanida y su uso para el tratamiento del cancer | |
| AR070212A1 (es) | Derivados de 4-(pirrolo[2,3-c]piridin-3-il)-pirimidinil-2-amina, proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores, metastasis tumoral y/o sida. | |
| AR072148A1 (es) | Derivados de quinoxalindiona | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR061010A1 (es) | Derivados de triazol i i | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |